Literature DB >> 33747899

Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response.

Daria Klusa1,2, Fabian Lohaus3, Giulia Furesi4, Martina Rauner4, Martina Benešová2, Mechthild Krause1,2,3,5, Ina Kurth2, Claudia Peitzsch1,2,5.   

Abstract

Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a 5-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the overall survival rate of patients drops dramatically. The metastatic cascade and organotropism of PCa cells are regulated by different cellular subtypes, organ microenvironment, and their interactions. This cross-talk leads to pre-metastatic niche formation that releases chemo-attractive factors enforcing the formation of distant metastasis. Biological characteristics of PCa metastasis impacting on metastatic sites, burden, and latency is of clinical relevance. Therefore, the implementation of modern hybrid imaging technologies into clinical routine increased the sensitivity to detect metastases at earlier stages. This enlarged the number of PCa patients diagnosed with a limited number of metastases, summarized as oligometastatic disease. These patients can be treated with androgen deprivation in combination with local-ablative radiotherapy or radiopharmaceuticals directed to metastatic sites. Unfortunately, the number of patients with disease recurrence is high due to the enormous heterogeneity within the oligometastatic patient population and the lack of available biomarkers with predictive potential for metastasis-directed radiotherapy. Another, so far unmet clinical need is the diagnosis of minimal residual disease before onset of clinical manifestation and/or early relapse after initial therapy. Here, monitoring of circulating and disseminating tumor cells in PCa patients during the course of radiotherapy may give us novel insight into how metastatic spread is influenced by radiotherapy and vice versa. In summary, this review critically compares current clinical concepts for metastatic PCa patients and discuss the implementation of recent preclinical findings improving our understanding of metastatic dissemination and radiotherapy resistance into standard of care.
Copyright © 2021 Klusa, Lohaus, Furesi, Rauner, Benešová, Krause, Kurth and Peitzsch.

Entities:  

Keywords:  circulating tumor cells; metastasis; prostate cancer; radiopharmacy; radiotherapy

Year:  2021        PMID: 33747899      PMCID: PMC7971112          DOI: 10.3389/fonc.2020.627379

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  8 in total

1.  GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis.

Authors:  Ricardo A Cordova; Jagannath Misra; Parth H Amin; Anglea J Klunk; Nur P Damayanti; Kenneth R Carlson; Andrew J Elmendorf; Hyeong-Geug Kim; Emily T Mirek; Bennet D Elzey; Marcus J Miller; X Charlie Dong; Liang Cheng; Tracy G Anthony; Robero Pili; Ronald C Wek; Kirk A Staschke
Journal:  Elife       Date:  2022-09-15       Impact factor: 8.713

2.  Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.

Authors:  Hongjun Fei; Xiongming Chen
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.

Authors:  Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

4.  Androgen receptor variant-7 regulation by tenascin-c induced src activation.

Authors:  Rintu Thomas; John Michael Jerome; Truong D Dang; Eric P Souto; Joshua N Mallam; David R Rowley
Journal:  Cell Commun Signal       Date:  2022-08-10       Impact factor: 7.525

Review 5.  Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies.

Authors:  Isis Wolf; Christian Gratzke; Philipp Wolf
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

6.  Reminiscence therapy-based care program serves as an optional nursing modality in alleviating anxiety and depression, improving quality of life in surgical prostate cancer patients.

Authors:  Ting Huang; Hongmei Su; Shi Zhang; Yawen Huang
Journal:  Int Urol Nephrol       Date:  2022-07-16       Impact factor: 2.266

Review 7.  Biological and Clinical Aspects of Metastatic Spinal Tumors.

Authors:  Jakub Litak; Wojciech Czyżewski; Michał Szymoniuk; Leon Sakwa; Barbara Pasierb; Joanna Litak; Zofia Hoffman; Piotr Kamieniak; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

8.  TPX2 Enhanced the Activation of the HGF/ETS-1 Pathway and Increased the Invasion of Endocrine-Independent Prostate Carcinoma Cells.

Authors:  Qinghong Zhou; Mingsheng Liu; Tao Shao; Pingbo Xie; Shaojie Zhu; Wei Wang; Qiong Miao; Jiaxi Peng; Peng Zhang
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.